Is pregabalin addictive? Dependence, withdrawal, and how to review treatment

What pregabalin is used for and why it is prescribed

Pregabalin, marketed as Lyrica and as various generic medications, belongs to the gabapentinoid group.

In the European Union, it is approved for adults with certain types of neuropathic pain, generalized anxiety disorder, and as add-on treatment for certain epileptic seizures. It is neither a benzodiazepine nor an antidepressant.

Supporting references: [3] EMA · Lyrica.

It acts on components of calcium channels in nerve cells, modifying the release of neurotransmitters involved in pain, anxiety, and epileptic activity. Its chemical relationship to GABA does not mean it works in the same way as a benzodiazepine.

Supporting references: [3] EMA · Lyrica.

It can provide substantial clinical benefit.

Information about dependence should not turn an appropriate prescription into a source of shame or alarm. What should be avoided is continuing or changing treatment without reviewing its benefits and any difficulties that are emerging.

Why this risk is being discussed again in 2026

On January 8, 2026, the UK’s MHRA announced improvements to warnings for gabapentinoids, benzodiazepines, and hypnotics known as Z-drugs.

The review aimed to help patients and professionals better understand dependence, addiction, tolerance, and withdrawal symptoms. This is action by the UK regulator, not a new Spanish rule or a withdrawal of pregabalin from the market.

Supporting references: [4] MHRA · Warnings and withdrawal · 2026.

Separately, a systematic review published in Drugs in 2026 brought together 100 studies on problematic use, dependence, or overdose involving gabapentin and pregabalin. Most were observational; others were case reports or clinical case series. Their findings reinforce the need for monitoring, particularly when other substances are also involved. They do not allow a single probability of addiction to be calculated for everyone who receives a prescription.

Supporting references: [5] Drugs · Systematic review · 2026.

The development is not the discovery that all use is dangerous. It is improving information and detecting problems earlier.

Dependence, tolerance, and addiction are not synonyms

This distinction prevents many misunderstandings.

They can coexist, but one does not automatically establish the others. The MHRA explicitly notes that being physically adapted to a medication does not necessarily mean having an addiction.

Supporting references: [4] MHRA · Warnings and withdrawal · 2026.

So I would not call someone an “addict” because they have followed their prescription and need gradual withdrawal.

Nor would I minimize the concerns of someone who acknowledges taking amounts different from those prescribed. In that situation, the pattern needs to be understood without turning the appointment into a moral interrogation.

“I take exactly what I was prescribed”: can withdrawal still occur?

Yes.

Cases have been published involving people who took usual doses, had no history of substance use disorders, and developed insomnia, anxiety, or other symptoms after abruptly stopping pregabalin. These case series show that it can happen; because of their size and design, they cannot tell us how often it happens across the patient population.

Supporting references: [6] PubMed · Withdrawal cases.

This has a practical implication:

Feeling unwell when stopping it does not prove that you have misused the medication.

The opposite conclusion should also be avoided: “because it was prescribed, any difficulty must be the original illness.” Medications can be helpful and still require precautions when discontinuing them.

What symptoms can occur when reducing pregabalin

The summary of product characteristics describes sleep disturbances, anxiety, nervousness, headache, nausea, diarrhea, sweating, dizziness, and pain. More serious symptoms, such as seizures or suicidal thoughts, have also been reported. Not everyone experiences them, and their intensity varies.

Supporting references: [1] CIMA · Pregabalin summary of product characteristics.

The NHS also lists restlessness, tremor, palpitations, and panic attacks among possible symptoms of abrupt discontinuation.

Supporting references: [2] NHS · Questions about pregabalin.

Not every deterioration should be normalized as something you “have to put up with.”

If new or intense symptoms develop during a change, the professional should assess what is causing them and whether the plan needs to be modified.

Withdrawal is a clinical process, not a test of endurance.

Has the anxiety returned, or is it withdrawal?

It can be difficult to tell.

Worsening soon after a reduction, symptoms that feel different from previous ones, or new symptoms may point toward withdrawal. But none of these clues can resolve every case on its own. The problem for which the medication was prescribed may also return, or another illness may develop.

Supporting references: [7] NICE NG215 · Rationale.

During a review, I would ask:

What changed first: the dose or the symptoms? Do they resemble the symptoms you had before? What is happening with sleep, pain, and functioning? Has another medication changed?

I would not attribute everything to withdrawal, but neither would I automatically interpret worsening as a relapse.

A bad experience when reducing it does not prove that you will never be able to change treatment. It means we need to understand better what happened.

Signs that warrant reviewing use as soon as possible

I would be particularly concerned if someone were increasing amounts without medical agreement, using the medication differently from the prescribed regimen, or feeling unable to control their doses.

Other relevant information includes repeatedly running out of medication early or noticing that a treatment that used to work no longer provides the same benefit. NICE recommends exploring these changes during reviews, without drawing conclusions from a single sign.

Supporting references: [8] NICE NG215 · Recommendations.

For example, requesting an early prescription does not establish an addiction: there may be a dosing error, an administrative issue, or an access problem. What matters is clarifying it.

These questions can help start the conversation:

• How much are you actually taking, and what are you hoping to achieve with each dose?
• Have you tried changing it on your own? What happened?
• Are you hiding some of your use, or are you worried about losing control?
• Does treatment improve your life, or is it creating difficulties you did not have before?

These are clinical questions, not a test for labeling yourself.

Combinations that require particular caution

Pregabalin can add to the sedative effects of opioids, benzodiazepines, and other central nervous system depressants. The MHRA also advises avoiding alcohol during treatment.

The risk is not limited to “being more relaxed”: excessive drowsiness can occur and, in serious situations, respiratory depression. Older adults, people with respiratory disease or renal impairment, and those taking other sedatives require particular monitoring. Cases have been reported even without concomitant opioids.

Supporting references: [9] MHRA · Respiratory depression.

The 2026 review also found evidence of increased overdose risk in certain contexts involving combinations with opioids or benzodiazepines. These data should be interpreted according to the population and pattern studied, not as an automatic prohibition of every prescribed combination.

Supporting references: [5] Drugs · Systematic review · 2026.

The key is for the prescriber to know the full treatment regimen and actual substance use.

If you experience dizziness, blurred vision, drowsiness, or difficulty concentrating, do not drive or operate machinery until the situation has been clarified. Pregabalin can affect these abilities, particularly when starting or changing treatment.

Supporting references: [2] NHS · Questions about pregabalin.

How do you stop taking pregabalin?

There is no universal schedule to copy from the internet.

The MHRA warns that some reductions, particularly from high doses, may take weeks or months. The pace should be adjusted to the response.

Supporting references: [4] MHRA · Warnings and withdrawal · 2026.

NICE recommends considering duration, dose, previous attempts, other medications, personal circumstances, and available support. It should be possible to review the plan if difficulties arise.

Supporting references: [8] NICE NG215 · Recommendations.

In an appointment, I would not start by handing over a rigid schedule. First, I would try to answer:

Is it still needed? Is the goal to stop it completely, reduce side effects, or stabilize use that has become disorganized?

Reducing the medication without treating the original problem can leave the plan incomplete

If pregabalin was prescribed for anxiety, a decision is needed about how that anxiety will be addressed. If it is being used for neuropathic pain, a pain management strategy needs to remain in place.

NICE recommends continuing to address the underlying condition during withdrawal. It also advises against treating withdrawal symptoms by simply substituting another medication associated with dependence.

Supporting references: [8] NICE NG215 · Recommendations.

This does not mean that every additional intervention is prohibited. It means that automatically adding sedatives can create a different problem without resolving the previous one.

Nor is switching to gabapentin simply a change of brand: they are different medications, and the transition requires supervision.

Supporting references: [2] NHS · Questions about pregabalin.

A good plan goes beyond removing something. It explains how the problem for which it was being taken will continue to be managed.

The role of psychotherapy and habits

In my approach, I would review sleep, pain, anxiety, alcohol use, and the situations in which the person takes additional doses. From there, I would propose specific interventions.

It may be necessary to work on the fear of feeling unwell, an automatic response to stress, or difficulty regulating emotions. But I would not present psychotherapy as a guarantee of avoiding every physical withdrawal symptom.

Specific evidence on psychological interventions to support gabapentinoid withdrawal is limited. NICE has stronger evidence for certain interventions for benzodiazepines and calls for more research for other medications. The findings should not be extrapolated as though they were equivalent.

Supporting references: [7] NICE NG215 · Rationale.

An integrative approach does not mean adding supplements to “cleanse” the body, either.

My goal would be to organize care that addresses real needs: rest, pain management, psychological treatment when appropriate, medical coordination, and sufficient support during changes.

What I would review at a first appointment

I would start by reconstructing the history without expecting the person to tell it perfectly.

The original indication. Why it was started, what symptoms were present, and what improvement was noticed.

The actual treatment regimen. Dose, timing, duration, changes, and other medications or substances. Not just what appears on the prescription.

Previous attempts. What was reduced, how quickly, which symptoms appeared, and how they resolved.

Current health. Anxiety, sleep, pain, mood, functioning, and relevant medical conditions. Renal function deserves attention because it affects pregabalin elimination and may require adjustments.

Supporting references: [3] EMA · Lyrica.

The person’s goal. They may want to stop it, understand what happened, reduce sedation, or regain control over dosing.

We would then agree on a plan explaining what will remain, what will change, when it will be reviewed, and what to do if problems arise.

I would not promise rapid withdrawal. Nor would I assume that every appointment must end with the medication being stopped.

Related reading: My antidepressant is not working: when to review treatment.

What if it still helps and I do not want to stop it?

That possibility needs to be taken into account.

The presence of risks does not automatically cancel out the benefits. Guidelines recommend considering continuation, adjustment, or withdrawal together with the person and reviewing the balance over time.

Supporting references: [8] NICE NG215 · Recommendations.

A review may conclude that it is still indicated, that something needs to change, or that a reduction should be planned.

Seeking help does not oblige you to accept immediate withdrawal or acknowledge an addiction that has not been diagnosed.

For me, the goal would be a decision that is understandable, shared, and open to review.

Can this assessment be done online?

It can be an entry point when the person is stable and the evaluation can be conducted safely.

Dr. Marc Agraz’s practice assesses problems related to substances and medications, with outpatient treatment when appropriate and coordination with more intensive services when needed. Care can take place in person in Lleida or by video consultation.

Service information: Assessment of addictions and medication-related problems in Lleida and online.

To prepare for the visit, bring a complete medication list, the amounts you actually use, and a brief explanation of the changes that concern you.

If a physical examination, lab tests, or in-person monitoring are needed, they must be arranged. A video call does not replace care for intoxication or complicated withdrawal.

Are you worried about dependence on pregabalin, or do you feel unwell when trying to reduce it?

An assessment can help distinguish between physical dependence, withdrawal symptoms, return of the original problem, and loss of control over use.

You do not need to stop it before seeking an assessment. Nor do you need to arrive with a conclusion already reached.

Dr. Marc Agraz · Integrative psychiatry and addictions
In-person care in Lleida and online appointments when clinically appropriate.

Having needed a medication is not a failure. Having difficulty reducing it is not a failure, either. What matters is not facing those difficulties without an evaluation and a plan.

Educational content for adults. Do not start, stop, or change medications based solely on this article. Scheduled appointments are not an emergency service.

Frequently asked questions

Sources and reference resources